Atrial FibrillationAPRONLESSNCT05319769
Non Fluoroscopic APpROach iN atriaL Fibrillation Ablation procEdureS
An observational study of Atrial Fibrillation, run by University Hospital of Ferrara at 1 site in Italy.
Trial summary
In electrophysiology, interventional procedures are often assisted by fluoroscopic guidance, exposing both patients and healthcare professionals to a considerable dose of radiation. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Atrial Fibrillation
- What is being tested?
- Atrial fibrillation ablation
- Type of treatment
- Surgery or procedure
- How many people
- 50 participants
- Where
- 1 siteItaly
- Study dates
- 1 Jun 2020to 31 Dec 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with atrial fibrillation (paroxysmal or persistent) treated with transcatheter ablation
Who may be able to join
- Paroxysmal or persistent atrial fibrillation
- Atrial fibrillation ablation performed during study period
- Clinical follow-up and ECG-Holter recording during follow-up
Who cannot join
- Age < 18 years
- Pregnancy
Trial locations and contacts
1 site in 1 country.
About this study
In electrophysiology, interventional procedures are often assisted by fluoroscopic guidance, exposing both patients and healthcare professionals to a considerable dose of radiation. Catheter ablation of atrial fibrillation has frequently involved the use of fluoroscopy: in fact, it incorporates greater complexity due to the need to perform the transseptal puncture.
A visible introducer in the 3D electro-anatomical mapping system (which does not involve the use of X-rays), has become an important tool for performing transseptal puncture: in particular, it is positioned at level of the oval fossa of the right atrium (puncture site); subsequently, the needle is introduced inside it; the intervention is guided both by electroanatomical mapping and by the use of intracardiac echocardiography for the identification of important anatomical landmarks.
Read more
The "zero rays" technique represents a valid alternative to fluoroscopic guidance, widely used and validated over the years. In fact, X-ray exposure in an atrial fibrillation ablation procedure can reach up to 60 mSv: the radiological risk makes it necessary to study safe and effective alternative techniques.
In this retrospective, observational and monocentric study, 50 catheter ablation procedures of atrial fibrillation will be examined, divided into two groups:
- 25 patients who performed this procedure according to the classic approach, ie under fluoroscopic guidance;
- 25 patients who performed this procedure using an ablative approach that involved the use of the introducer in combination with the 3D EAM system and intracardiac echocardiography.
Clinical efficacy will be assessed through a cardiological checkup and 24-hour electrocardiographic recording (ECG Holter) at 6 months.
Read the detailed description
Atrial fibrillation (AF) is the most common sustained adult tachyarrhythmia found in clinical practice. The prevalence of this arrhythmia in the general population varies from 2 to 4% and increases significantly in elderly patients and in carriers of diseases such as arterial hypertension, heart failure, coronary and valvular disease, obesity, diabetes mellitus and chronic kidney disease. In addition to being a marker of underlying heart or vascular disease, FA in itself is accompanied by an increased incidence of ischemic stroke, heart failure and dementia. The mechanisms underlying this arrhythmia are still debated, but seem to involve electrical and structural alterations of the atrium that constitute a morpho-functional substrate that facilitate its development.
Traditionally, five types of atrial fibrillation are distinguished, based on presentation, duration and term:
- Newly diagnosed AF: first finding of AF, regardless of the duration, presence and severity of symptoms;
- Paroxysmal AF: AF that resolves within seven days (spontaneously or through cardioversion);
- Persistent AF: AF that lasts more than seven days or is cardioverted after seven days;
- Long lasting AF: AF that lasts more than a year continuously, when a rhythm control strategy has been adopted.
- Permanent AF: AF accepted by the patient (and by the attending physician) for which no further attempt to control the rhythm is undertaken.
Treatment include heart rate and / or rhythm control strategies, prevention of cerebral thromboembolism and reduction / elimination of symptoms, as well as control of major cardiovascular risk factors. The decision about the implementation of therapeutic strategies aimed at restoring and maintaining sinus rhythm must be shared between doctor and patient, weighing on the one hand the effect on quality of life and symptoms, and on the other the risk of toxic effects of drugs. used. When AF has been on for less than a year, an early rhythm control strategy has been shown to reduce the composite outcome of cardiovascular death, stroke, hospitalization for heart failure or acute coronary syndrome in the EAST-AFNET 4 clinical trial.
Trans catheter ablation is a well-established treatment for the reduction of AF relapses and is proposed in cases of paroxysmal and persistent AF. It is a procedure that consists in the antral circumferential disconnection of the pulmonary veins by radiofrequency, laser or cryoblation. It is a safe and effective technique for maintaining sinus rhythm and for improving symptoms. When antiarrhythmic drugs fail in rhythm control, the current ESC 2020 Guidelines place trans-catheter ablation in class I for paroxysmal and persistent AF with or without major risk factors for recurrence, while as a first therapeutic approach it is in class IIa for paroxysmal AF and IIb for persistent AF without major risk factors for relapse.
Advanced three-dimensional electro-anatomical mapping systems (3D EAM) have revolutionized the transcatheter ablative approach, allowing a new approach to the study of complex arrhythmias, such as FA. All the mapping systems, even if based on different principles, allow a precise localization of the scaler catheter, starting from the vascular access up to the heart chambers. While the catheter scans the different cardiac structures, the system records information about the catheter's position and uses the spatial and electrical data to create an accurate reproduction of the 3D geometry of the cardiac structures. All this has led to a reduction in the use of fluoroscopy and, in particular for the ablation of AF, there has been a reduction in radiation during these procedures even if a complete elimination has not yet been possible.
Intracardiac echocardiography is an imaging technique capable of visualizing heart structures in real time and with very high spatial resolution, as well as monitoring the position of the catheter within the heart chambers and quickly identifying any procedural complications, such as the formation of thrombus or pericardial effusion. A further advantage is represented by the reduction of the scan times. For these reasons, intracardiac echocardiography has largely replaced transesophageal echocardiography in many interventional procedures, including those of electrophysiology. In fact, intracardiac echocardiography allows the integration of images in real time with electro-anatomical mapping systems, allowing to map those structures that are not viewable under fluoroscopy, such as the atrial septum.
A bi-directional, deflectable guide introducer capable of being visualized on the 3D mapping system allows the visualization in real time, allowing to increase the efficiency during the mapping and positioning of the scaler catheter, reducing, up to zero, the scan times. It also has 2-degree bidirectional deflection capability, reaching up to 180 degrees in both directions.
Furthermore, it is extremely performing during the atrial septal puncture procedures: when, in fact, a dilator is introduced through introducer to perform the transseptal puncture, the presence of a smooth interface between the dilator and the tip of introducer allows access more easily to the left atrium, reducing the force required to advance the system through the atrial septum by 33%.
The fluoroscopic approach is widely validated and has represented for years the gold standard in electrophysiological study and ablation procedures. However, this approach exposes the operator and the patient to a high dose of radiation: in fact, during an AF ablation procedure, the radiological exposure can reach up to 60 mSv, thus increasing the absolute risk of developing lifetime cancer by 0.08%. It is therefore very necessary to apply the principles of ALARA (a slow as reasonably achievable) as established by the consent document of the American College of Cardiology of 1998.
Recently the trans catheter ablation procedures of AF have undergone a major increase. Considering, therefore, the wide diffusion of this technique and the high radiological exposure linked to the transseptal puncture and the isolation of the pulmonary veins, promoting an approach without radiological exposure becomes extremely crucial.
The rationale of this study is to evaluate the clinical and procedural features of an ablative approach using the steerable introducer in combination with the 3D EAM system and intracardiac echocardiography: the combination of these elements is potentially able to significantly reduce, to zero, the scanning times and to reduce procedural times, guaranteeing efficacy and safety. Complications will also be assessed at 30 days and the effectiveness of the procedure at six months.
- Conditions
- Atrial Fibrillation
- Being tested
- Atrial fibrillation ablation
- Keywords
- atrial fibrillation, ablation, radiofrequency, intracardiac echocardiography, zero fluoroscopy, arrhythmias
- Medical subject headings
- Atrial Fibrillation, Arrhythmias, Cardiac
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Atrial fibrillation ablationProcedure or surgery
Pulmonary vein isolation
| Study group | Role | What they receive |
|---|---|---|
| Zero fluoroscopy | Zero fluoroscopy Patients undergoing AF ablation using the steerable introducer in combination with the 3D EAM system and intracardiac echocardiography.
Reconstruction of a bipolar map of the right atrium with a mapping catheter. Then, the interatrial septum is reconstructed and the oval fossa is defined. Transseptal puncture is performed using the steerable introducer (which can be viewed on the EAM) through which, a transseptal needle is introduced. The introducer is positioned at the fossa ovalis. The transseptal needle is advanced to perform the puncture of the septum. After accessing the left atrium, the mapping catheter is introduced iusing the introducer, with which all the structures of the left atrium are mapped. In addition, with intracardiac echocardiography, it is possible to identify important structures such as the pulmonary veins and the esophagus. The pulmonary veins are isolated by means of a catheter. Receives: Procedure: Atrial fibrillation ablation | |
| Traditional approach | Traditional approach Patients who have undergone atrial fibrillation ablation procedure using the traditional approach.
The procedure is based on 3D reconstruction using intracardiac ultrasound first and then electroanatomical mapping of the left atrium through a transseptal approach guided by integration of fluoroscopy and intracardiac ultrasound. The transseptal puncture is performed using a transseptal needle which is brought into place using a long introducer with a dilator. The fluoroscopic support is essential as the introducer is not viewable with 3D mapping systems. After accessing the left atrium, through the previously used introducer, a mapping catheter is taken to the left atrium for electro-anatomical reconstruction. Subsequently, the antral pulmonary veins are isolated by means of an ablator catheter with irrigated tip. Receives: Procedure: Atrial fibrillation ablation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fluoroscopy time
Time of X-ray exposure
Measured: Intraprocedure
DAP
Dose area product
Measured: Intraprocedure
Procedural time
Total procedure time
Measured: Intraprocedure
Secondary outcomes (3)
Time for PVI
Pulmonary veins isolation time
Measured: Intraprocedure
Complications
Procedural complications, percardial effusion, groin hematoma, thromboembolism
Measured: 30 days
Absence of atrial fibrillation recurrence
Freedom from new episodes of arrhythmias
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2022
- Study start1 Jun 2020
- Primary completion30 Jun 2021
- Study completion31 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital of Ferrara
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Matteo Bertini, University Hospital of Ferrara
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05319769
- Sponsor's protocol ID
- 234/2022/Oss/AOUFe
- Acronym
- APRONLESS
- Status last verified
- Mar 2022
- First submitted
- 31 Mar 2022
- Last updated
- 8 Apr 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non Fluoroscopic APpROach iN atriaL Fibrillation Ablation procEdureS
- ClinicalTrials.gov ID
- NCT05319769
- Acronym / sponsor ID
- APRONLESS / 234/2022/Oss/AOUFe
- Conditions
- Atrial Fibrillation
- Keywords
- atrial fibrillation, ablation, radiofrequency, intracardiac echocardiography, zero fluoroscopy, arrhythmias
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- University Hospital of FerraraUniversity, hospital or other
- Study start
- 1 Jun 2020 (actual)
- Primary completion
- 30 Jun 2021 (actual)
- Study completion
- 31 Dec 2021 (actual)
- First posted
- 8 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In electrophysiology, interventional procedures are often assisted by fluoroscopic guidance, exposing both patients and healthcare professionals to a considerable dose of radiation. Catheter ablation of atrial fibrillation has frequently involved the use of fluoroscopy: in fact, it incorporates greater complexity due to the need to perform the transseptal puncture.
A visible introducer in the 3D electro-anatomical mapping system (which does not involve the use of X-rays), has become an important tool for performing transseptal puncture: in particular, it is positioned at level of the oval fossa of the right atrium (puncture site); subsequently, the needle is introduced inside it; the intervention is guided both by electroanatomical mapping and by the use of intracardiac echocardiography for the identification of important anatomical landmarks.
The "zero rays" technique represents a valid alternative to fluoroscopic guidance, widely used and validated over the years. In fact, X-ray exposure in an atrial fibrillation ablation procedure can reach up to 60 mSv: the radiological risk makes it necessary to study safe and effective alternative techniques.
In this retrospective, observational and monocentric study, 50 catheter ablation procedures of atrial fibrillation will be examined, divided into two groups:
- 25 patients who performed this procedure according to the classic approach, ie under fluoroscopic guidance;
- 25 patients who performed this procedure using an ablative approach that involved the use of the introducer in combination with the 3D EAM system and intracardiac echocardiography.
Clinical efficacy will be assessed through a cardiological checkup and 24-hour electrocardiographic recording (ECG Holter) at 6 months.
Detailed description
Atrial fibrillation (AF) is the most common sustained adult tachyarrhythmia found in clinical practice. The prevalence of this arrhythmia in the general population varies from 2 to 4% and increases significantly in elderly patients and in carriers of diseases such as arterial hypertension, heart failure, coronary and valvular disease, obesity, diabetes mellitus and chronic kidney disease. In addition to being a marker of underlying heart or vascular disease, FA in itself is accompanied by an increased incidence of ischemic stroke, heart failure and dementia. The mechanisms underlying this arrhythmia are still debated, but seem to involve electrical and structural alterations of the atrium that constitute a morpho-functional substrate that facilitate its development.
Traditionally, five types of atrial fibrillation are distinguished, based on presentation, duration and term:
- Newly diagnosed AF: first finding of AF, regardless of the duration, presence and severity of symptoms;
- Paroxysmal AF: AF that resolves within seven days (spontaneously or through cardioversion);
- Persistent AF: AF that lasts more than seven days or is cardioverted after seven days;
- Long lasting AF: AF that lasts more than a year continuously, when a rhythm control strategy has been adopted.
- Permanent AF: AF accepted by the patient (and by the attending physician) for which no further attempt to control the rhythm is undertaken.
Treatment include heart rate and / or rhythm control strategies, prevention of cerebral thromboembolism and reduction / elimination of symptoms, as well as control of major cardiovascular risk factors. The decision about the implementation of therapeutic strategies aimed at restoring and maintaining sinus rhythm must be shared between doctor and patient, weighing on the one hand the effect on quality of life and symptoms, and on the other the risk of toxic effects of drugs. used. When AF has been on for less than a year, an early rhythm control strategy has been shown to reduce the composite outcome of cardiovascular death, stroke, hospitalization for heart failure or acute coronary syndrome in the EAST-AFNET 4 clinical trial.
Trans catheter ablation is a well-established treatment for the reduction of AF relapses and is proposed in cases of paroxysmal and persistent AF. It is a procedure that consists in the antral circumferential disconnection of the pulmonary veins by radiofrequency, laser or cryoblation. It is a safe and effective technique for maintaining sinus rhythm and for improving symptoms. When antiarrhythmic drugs fail in rhythm control, the current ESC 2020 Guidelines place trans-catheter ablation in class I for paroxysmal and persistent AF with or without major risk factors for recurrence, while as a first therapeutic approach it is in class IIa for paroxysmal AF and IIb for persistent AF without major risk factors for relapse.
Advanced three-dimensional electro-anatomical mapping systems (3D EAM) have revolutionized the transcatheter ablative approach, allowing a new approach to the study of complex arrhythmias, such as FA. All the mapping systems, even if based on different principles, allow a precise localization of the scaler catheter, starting from the vascular access up to the heart chambers. While the catheter scans the different cardiac structures, the system records information about the catheter's position and uses the spatial and electrical data to create an accurate reproduction of the 3D geometry of the cardiac structures. All this has led to a reduction in the use of fluoroscopy and, in particular for the ablation of AF, there has been a reduction in radiation during these procedures even if a complete elimination has not yet been possible.
Intracardiac echocardiography is an imaging technique capable of visualizing heart structures in real time and with very high spatial resolution, as well as monitoring the position of the catheter within the heart chambers and quickly identifying any procedural complications, such as the formation of thrombus or pericardial effusion. A further advantage is represented by the reduction of the scan times. For these reasons, intracardiac echocardiography has largely replaced transesophageal echocardiography in many interventional procedures, including those of electrophysiology. In fact, intracardiac echocardiography allows the integration of images in real time with electro-anatomical mapping systems, allowing to map those structures that are not viewable under fluoroscopy, such as the atrial septum.
A bi-directional, deflectable guide introducer capable of being visualized on the 3D mapping system allows the visualization in real time, allowing to increase the efficiency during the mapping and positioning of the scaler catheter, reducing, up to zero, the scan times. It also has 2-degree bidirectional deflection capability, reaching up to 180 degrees in both directions.
Furthermore, it is extremely performing during the atrial septal puncture procedures: when, in fact, a dilator is introduced through introducer to perform the transseptal puncture, the presence of a smooth interface between the dilator and the tip of introducer allows access more easily to the left atrium, reducing the force required to advance the system through the atrial septum by 33%.
The fluoroscopic approach is widely validated and has represented for years the gold standard in electrophysiological study and ablation procedures. However, this approach exposes the operator and the patient to a high dose of radiation: in fact, during an AF ablation procedure, the radiological exposure can reach up to 60 mSv, thus increasing the absolute risk of developing lifetime cancer by 0.08%. It is therefore very necessary to apply the principles of ALARA (a slow as reasonably achievable) as established by the consent document of the American College of Cardiology of 1998.
Recently the trans catheter ablation procedures of AF have undergone a major increase. Considering, therefore, the wide diffusion of this technique and the high radiological exposure linked to the transseptal puncture and the isolation of the pulmonary veins, promoting an approach without radiological exposure becomes extremely crucial.
The rationale of this study is to evaluate the clinical and procedural features of an ablative approach using the steerable introducer in combination with the 3D EAM system and intracardiac echocardiography: the combination of these elements is potentially able to significantly reduce, to zero, the scanning times and to reduce procedural times, guaranteeing efficacy and safety. Complications will also be assessed at 30 days and the effectiveness of the procedure at six months.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Zero fluoroscopy | – | Procedure: Atrial fibrillation ablationZero fluoroscopy Patients undergoing AF ablation using the steerable introducer in combination with the 3D EAM system and intracardiac echocardiography. Reconstruction of a bipolar map of the right atrium with a mapping catheter. Then, the interatrial septum is reconstructed and the oval fossa is defined. Transseptal puncture is performed using the steerable introducer (which can be viewed on the EAM) through which, a transseptal needle is introduced. The introducer is positioned at the fossa ovalis. The transseptal needle is advanced to perform the puncture of the septum. After accessing the left atrium, the mapping catheter is introduced iusing the introducer, with which all the structures of the left atrium are mapped. In addition, with intracardiac echocardiography, it is possible to identify important structures such as the pulmonary veins and the esophagus. The pulmonary veins are isolated by means of a catheter. |
| Traditional approach | – | Procedure: Atrial fibrillation ablationTraditional approach Patients who have undergone atrial fibrillation ablation procedure using the traditional approach. The procedure is based on 3D reconstruction using intracardiac ultrasound first and then electroanatomical mapping of the left atrium through a transseptal approach guided by integration of fluoroscopy and intracardiac ultrasound. The transseptal puncture is performed using a transseptal needle which is brought into place using a long introducer with a dilator. The fluoroscopic support is essential as the introducer is not viewable with 3D mapping systems. After accessing the left atrium, through the previously used introducer, a mapping catheter is taken to the left atrium for electro-anatomical reconstruction. Subsequently, the antral pulmonary veins are isolated by means of an ablator catheter with irrigated tip. |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with atrial fibrillation (paroxysmal or persistent) treated with transcatheter ablation
Key inclusion criteria (3 listed)
- Paroxysmal or persistent atrial fibrillation
- Atrial fibrillation ablation performed during study period
- Clinical follow-up and ECG-Holter recording during follow-up
Key exclusion criteria (2 listed)
- Age < 18 years
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Atrial fibrillation ablationPulmonary vein isolation | Procedure or surgery | Traditional approach, Zero fluoroscopy |
Primary outcome
Fluoroscopy time
Time frame: Intraprocedure
Time of X-ray exposure
DAP
Time frame: Intraprocedure
Dose area product
Procedural time
Time frame: Intraprocedure
Total procedure time
3 secondary outcomes
Time for PVI
Time frame: Intraprocedure
Complications
Time frame: 30 days
Absence of atrial fibrillation recurrence
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2022.
Related trials for Atrial Fibrillation
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruitingObservational study
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
Concomitant Procedures, Atrial Fibrillation
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Ischemic Stroke, Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation, run by University Hospital of Ferrara at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fluoroscopy time (time frame: Intraprocedure). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2022.